Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH2 | Q6NS38 | 2/20 | 0.69 |
| ▸ | HPGDS | O60760 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29544523 | 1.00 | ALKBH2 (0.69) | ALKBH2HPGDSMAPTHPGDHTT | |
| SCHEMBL17365305 | 0.88 | MAPT (0.53) | ALKBH2HPGDSMAPTHPGDHTT | |
| SCHEMBL17563306 | 0.84 | MAPT (0.50) | ALKBH2HPGDSMAPTHPGDHTT | |
| SCHEMBL9956086 | 0.84 | ALKBH2 (0.62) | ALKBH2HPGDSMAPTHPGDHTT | |
| SCHEMBL27575419 | 0.84 | ALKBH2 (0.77) | ALKBH2HPGDSMAPTHPGDHTT | |
| SCHEMBL7510493 | 0.83 | ALKBH2 (0.71) | ALKBH2HPGDSMAPTHPGDHTT | |
| SCHEMBL2860519 | 0.83 | ALKBH2 (0.71) | ALKBH2HPGDSMAPTHPGDHTT | |
| SCHEMBL10998710 | 0.82 | EGLN1 (0.66) | ALKBH2HPGDSKEAP1NFE2L2EGLN1 | |
| SCHEMBL70281 | 0.82 | ALKBH2 (1.00) | ALKBH2HPGDSMAPTHPGDHTT | |
| SCHEMBL3374557 | 0.82 | ALKBH2 (0.69) | ALKBH2HPGDSMAPTHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| US-20210206762-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2021-07-08 | — | — | US | disclosed |
| EP-3252050-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-1360489-A1 | LOW AFFINITY SCREENING METHOD | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2003-11-12 | — | — | EP | disclosed |
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1305304-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | disclosed |
| EP-1291341-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002010146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | MPL, THPO, TEK | ALKBH2 4485/4885HPGDS 144/4885MAPT 4866/4885 |
| US-20210206762-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MAP4K2, MAP3K1, MAP3K19 | ALKBH2 3297/4885HPGDS 1827/4885MAPT 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.